Chemiesynth vapi Limited has announced the reconstitution of its Nomination and Remuneration Committee following a board meeting held on 13-02-2026. The changes were implemented with immediate effect to ensure compliance with regulatory requirements under the Companies Act, 2013 and SEBI listing regulations.

Committee Restructuring Details

The board approved significant changes to the committee composition to maintain compliance with Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sandip Zaveri, who previously served as a Promoter Director on the committee, has ceased to be a member. In his place, Mr. Satish Zaveri, Promoter Non-Executive Director, has been appointed as a new member of the Nomination and Remuneration Committee.

Reconstituted Committee Composition

The newly reconstituted Nomination and Remuneration Committee comprises the following members:

The committee maintains a balanced composition with two independent directors and one non-executive non-independent director, ensuring proper governance structure as mandated by regulatory frameworks.

Regulatory Compliance

The company has confirmed that the reconstituted Nomination and Remuneration Committee is duly constituted in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. This restructuring demonstrates the company's commitment to maintaining proper corporate governance standards and adhering to statutory requirements.

The announcement was made through a formal communication to BSE Limited, where the company's shares are listed under scrip code 539230. The notification was signed by Mr. Sandip Zaveri, Managing Director (DIN: 00158876), and digitally authenticated on 2026.02.13.

Chemiesynth Vapi Limited, a Gujarat-based chemical company, announced the unexpected passing of its Chief Financial Officer, Parimal Amratlal Desai, on September 7, 2025. The company informed the BSE Limited of this unfortunate event on September 8, 2025, in compliance with SEBI regulations.

A Legacy of Leadership

Mr. Desai had been an integral part of Chemiesynth (Vapi) Limited for two decades, having served as the company's CFO since 2015. His sudden demise has been described by the company as an "irreparable loss," highlighting the significant impact he had on the organization during his tenure.

Career Highlights

During his 20-year career at Chemiesynth (Vapi) Limited, Mr. Desai played crucial leadership roles that contributed to the company's growth and success. His appointment as CFO in 2015 marked a period of visionary leadership that greatly benefited the company.

Company's Response

In a statement to the BSE, Chemiesynth (Vapi) Limited expressed deep sorrow over Mr. Desai's passing:

"Mr. Parimal A Desai played crucial leadership roles through his 20 years career at Chemiesynth (Vapi) Limited. He was appointed as a CFO in 2015 and the Company immensely benefitted from his vision and leadership during his tenure. His sudden and unexpected passing away will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy, sorrow and condolences to Desai family."

Regulatory Compliance

The company promptly informed the stock exchange about this material event on September 8, 2025, in accordance with Schedule III of Regulation 30 of SEBI (LODR) Regulations, 2015. This swift action demonstrates Chemiesynth (Vapi) Limited's commitment to transparency and regulatory compliance.

As the company navigates this difficult period, the focus will likely turn to ensuring continuity in financial leadership. Chemiesynth (Vapi) Limited will undoubtedly feel the impact of losing such a long-standing and influential member of its executive team.